Previous 10 | Next 10 |
Travere Therapeutics (TVTX) has completed enrollment in the Phase 3 DUPLEX study evaluating sparsentan for the treatment of focal segmental glomerulosclerosis ((FSGS)), a rare kidney condition that often leads to end-stage kidney disease ((ESKD)). Topline efficacy data is expected in Q1 of 20...
SAN DIEGO, Nov. 30, 2020 (GLOBE NEWSWIRE) -- Travere Therapeutics (NASDAQ: TVTX) today announced completion of patient enrollment in the Phase 3 DUPLEX Study. The pivotal DUPLEX Study is evaluating the safety and efficacy of sparsentan for the treatment of focal segmental glomerulosclerosis...
Retrophin (RTRX) says it has changed its global corporate name to Travere Therapeutics, and will begin trading under the new ticker symbol TVTX at market open on Nov. 19.Retrophin had stood for "Re(place) (dys)trophin," according to disgraced founder Martin Shkreli, but CEO Eric Dube say...
New name reflects dedication to patient- inspired mission of identifying, developing and delivering life-changing rare disease therapies Company’s s hares to t rade u nder n ew t icker s ymbol TVTX on Novem...
SAN DIEGO, Nov. 12, 2020 (GLOBE NEWSWIRE) -- Retrophin, Inc. (NASDAQ: RTRX) today announced the completion of its previously announced acquisition of Orphan Technologies Limited, a privately held, clinical-stage biopharmaceutical company focused on the development of product candidate OT-58...
Retrophin, Inc. (RTRX) Q3 2020 Earnings Conference Call November 5, 2020 4:30 PM ET Company Participants Chris Cline – Vice President, Investor Relations and Corporate Communications Eric Dube – Chief Executive Officer Noah Rosenberg – Chief Medical Officer Peter Heerma &...
Retrophin (RTRX): Q3 GAAP EPS of -$0.44 beats by $0.07.Revenue of $51.14M (+15.3% Y/Y) beats by $3.39M.Press Release For further details see: Retrophin EPS beats by $0.07, beats on revenue
Pivotal DUPLEX Study of sparsentan in FSGS nears completion of enrollment; topline proteinuria data expected 1Q21 Pivotal PROTECT Study achieved enrollment of 280 th patient with IgAN to enable topline proteinuria data in 3Q21 Expanding pipeline of potential first-in-c...
Retrophin (RTRX) has agreed to acquire a privately-held Orphan Technologies and add OT-58, a novel enzyme replacement therapy in Phase 1/2 trial for the treatment of classical homocystinuria ((HCU)), a rare metabolic disorder characterized by elevated levels of plasma homocysteine t...
Agreement a dd s OT-58, a novel enzyme replacement therapy in Phase 1/2 development for the treatment of classical homocystinuria Compelling strategic fit that will expand p ipeline of potential first-in-class therapies targeting rar...
News, Short Squeeze, Breakout and More Instantly...
SAN DIEGO, Nov. 30, 2020 (GLOBE NEWSWIRE) -- Travere Therapeutics (NASDAQ: TVTX) today announced completion of patient enrollment in the Phase 3 DUPLEX Study. The pivotal DUPLEX Study is evaluating the safety and efficacy of sparsentan for the treatment of focal segmental glomerulosclerosis...
New name reflects dedication to patient- inspired mission of identifying, developing and delivering life-changing rare disease therapies Company’s s hares to t rade u nder n ew t icker s ymbol TVTX on Novem...
SAN DIEGO, Nov. 12, 2020 (GLOBE NEWSWIRE) -- Retrophin, Inc. (NASDAQ: RTRX) today announced the completion of its previously announced acquisition of Orphan Technologies Limited, a privately held, clinical-stage biopharmaceutical company focused on the development of product candidate OT-58...